Enhancing GSH, mainly through NAC, GSH precursors or pro-GSH compound administration, becomes a potential treatment option for SARS-CoV-2 infection and COVID-19 disease by reducing oxidative stress and cytokine expression especially in diabetic patients at risk of more severe disease (Singh et al., 2022)
GLP-1 carries most of the appetite effect, glucagon drives much of the liver- and visceral-fat loss, and GIP improves insulin handling while buffering some GLP-1-related nausea
Consistency in timing is important, and patients should be encouraged to take the medication at the same time each day to maintain stable drug levels
Note that Saxenda is not currently covered by the PAP
A significant barrier to access is the high out-of-pocket costs of these medications, particularly for more expensive drugs like newer GLP-1 receptor agonists [49]